Skip to main content
Premium Trial:

Request an Annual Quote

Human Protein Atlas adopts Origene's Over-expression Lysates

Premium

This story originally ran on Nov. 11.

The operators of the Human Protein Atlas program have adopted Origene Technologies' Verify Tagged Antigen over-expression lysates, the Rockville-based company said this week.

The HPA, operated by the Royal Institute of Technology in Stockholm, is a project to map the human proteome using antibody-based technologies. Origene's Verify Tagged Antigen over-expression lysates are full-length human proteins for functional studies and antibody validation, according to the company's website.

In a statement, Matthias Uhlen, program director of HPA, said that in pilot testing, using Origene's over-expression cell lysates as Western blot controls, he and his staff were able to increase the antibody validation success rate to 80 percent from 30 percent.

"Generating high quality mono-specific antibodies in a high-throughput manner is critical for the success of the program," he said.

Antibody quality is a longstanding problem that continues to plague antibody-based proteomics. Wei-Wu He, CEO of Origene, said in a statement that the company is "committed to provide both products and technical resources" to HPA, and added that the over-expression lysates "are the beginning of a series of products aimed at antibody validation and biomarker discovery."

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.